search
Back to results

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Primary Purpose

Overactive Bladder Syndrome

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
AV608
Sponsored by
Avera Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overactive Bladder Syndrome focused on measuring Idiopathic Detrusor Overactivity, NK-1 Receptor Antagonist, Neurokinin, Urge Incontinence

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female, 18 to 65 years of age, inclusive A current primary diagnosis of OAB Idiopathic detrusor overactivity, demonstrated by a urodynamic observation Evidence of frequency in combination with urinary urgency Written informed consent form Willingness to avoid pregnancy and practice adequate birth control Negative serum pregnancy test Agrees to refrain from blood donation during the course of the study Exclusion Criteria: Subjects who are pregnant or lactating Clinically significant abnormality or clinically significant unstable medical condition QTc interval of 470 msec or greater at Visit 1 Predominant stress urinary incontinence versus urge urinary incontinence based on subject history Neurogenic bladder (e.g. associated with spinal cord injury, multiple sclerosis, etc.) Anatomic or structural abnormalities possibly causing urinary incontinence or urgency, including but not limited to urogenital prolapse stage 2 or more according to the Pelvic Organ Prolapse Quantification (POP-Q) system Urological or gynecological surgery within 3 months of the baseline urodynamic assessment Current UTI or frequent UTIs (i.e., greater than or equal to 4 UTIs per year), interstitial cystitis, hematuria of unknown cause, or use of indwelling catheter Electro-stimulation therapy, bladder training, or physiotherapy for bladder control within 2 weeks of Visit 1 History (within 1 year of Screening) of alcohol or substance dependence (except nicotine dependence) according to DSM-IV-TR criteria History of any kind of cancer within the last 2 years Existing non-malignant tumors that could compromise the function and/or anatomy of the lower urinary tract

Sites / Locations

Outcomes

Primary Outcome Measures

Comparison between treatment groups of the change from baseline in maximum cystometric bladder capacity

Secondary Outcome Measures

Delay of the first involuntary detrusor contraction associated with symptomatic urgency
Urgency, frequency and urge incontinence events as recorded in the Subject Micturition Diary
Urgency Perception Scale

Full Information

First Posted
June 8, 2006
Last Updated
February 15, 2008
Sponsor
Avera Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00335660
Brief Title
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
Study Type
Interventional

2. Study Status

Record Verification Date
February 2008
Overall Recruitment Status
Terminated
Why Stopped
Animal Safety Data
Study Start Date
June 2006 (undefined)
Primary Completion Date
June 2007 (Actual)
Study Completion Date
September 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Avera Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Idiopathic Detrusor Overactivity.
Detailed Description
This is a Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of AV608 in subjects with idiopathic detrusor overactivity. Female subjects between 18 and 65 years of age with a diagnosis of Overactive Bladder Syndrome and urodynamic observation of involuntary detrusor contractions during the filling phase will be eligible for the trial. Eligible subjects will complete a baseline urodynamic assessment. All subjects who participate in the study will receive 3 weeks of treatment with AV608 or placebo. At the end of the treatment period, subjects will complete a second urodynamic assessment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder Syndrome
Keywords
Idiopathic Detrusor Overactivity, NK-1 Receptor Antagonist, Neurokinin, Urge Incontinence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
62 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
AV608
Primary Outcome Measure Information:
Title
Comparison between treatment groups of the change from baseline in maximum cystometric bladder capacity
Secondary Outcome Measure Information:
Title
Delay of the first involuntary detrusor contraction associated with symptomatic urgency
Title
Urgency, frequency and urge incontinence events as recorded in the Subject Micturition Diary
Title
Urgency Perception Scale

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female, 18 to 65 years of age, inclusive A current primary diagnosis of OAB Idiopathic detrusor overactivity, demonstrated by a urodynamic observation Evidence of frequency in combination with urinary urgency Written informed consent form Willingness to avoid pregnancy and practice adequate birth control Negative serum pregnancy test Agrees to refrain from blood donation during the course of the study Exclusion Criteria: Subjects who are pregnant or lactating Clinically significant abnormality or clinically significant unstable medical condition QTc interval of 470 msec or greater at Visit 1 Predominant stress urinary incontinence versus urge urinary incontinence based on subject history Neurogenic bladder (e.g. associated with spinal cord injury, multiple sclerosis, etc.) Anatomic or structural abnormalities possibly causing urinary incontinence or urgency, including but not limited to urogenital prolapse stage 2 or more according to the Pelvic Organ Prolapse Quantification (POP-Q) system Urological or gynecological surgery within 3 months of the baseline urodynamic assessment Current UTI or frequent UTIs (i.e., greater than or equal to 4 UTIs per year), interstitial cystitis, hematuria of unknown cause, or use of indwelling catheter Electro-stimulation therapy, bladder training, or physiotherapy for bladder control within 2 weeks of Visit 1 History (within 1 year of Screening) of alcohol or substance dependence (except nicotine dependence) according to DSM-IV-TR criteria History of any kind of cancer within the last 2 years Existing non-malignant tumors that could compromise the function and/or anatomy of the lower urinary tract
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Linda Cardozo, MD FRCOG
Organizational Affiliation
King's College Hospital NHS Trust
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Joao Siffert, MD
Organizational Affiliation
Avera Pharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
City
Amsterdam
Country
Netherlands
City
Nieuwegein
Country
Netherlands
City
Zeist
Country
Netherlands
City
Birmingham
State/Province
England
Country
United Kingdom
City
Blackburn
State/Province
England
Country
United Kingdom
City
Chertsey
State/Province
England
Country
United Kingdom
City
Hull
State/Province
England
Country
United Kingdom
City
Leeds
State/Province
England
Country
United Kingdom
City
Liverpool
State/Province
England
Country
United Kingdom
City
London
State/Province
England
Country
United Kingdom
City
Plymouth
State/Province
England
Country
United Kingdom
City
Sheffield
State/Province
England
Country
United Kingdom
City
Falkirk
State/Province
Scotland
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

We'll reach out to this number within 24 hrs